Owners, management and financials
CVR: 42287067
DKK 5,875,000
Gross profit
Net result: DKK -61,325,000
Drug Development Consulting Holding ApS (100%)
CVR · view owners
René Holmen Pedersen
Board: Niels Peder Nielsen (chair) and 3 members
CVR · view management
Active
Founded 8 April 2021
CVR · view overview
2 employees
Annual report 2025 · average
Director role ended: Rasmus Koch Nelund
CVR · 28/02/2025
View the full event history
Drug Development Consulting BidCo ApS is a Danish company of the type Anpartsselskab based in Brøndby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The management consists of René Holmen Pedersen. The board consists of Niels Peder Nielsen (chair), Alejandra Maria Cristina Bonifacini Mørk, Rafael Natanek and Redmar Koene. The company is owned by Drug Development Consulting Holding ApS. According to the 2025 annual report, the company had an average of 2 employees. In 2025, the company reported a gross profit of DKK 5,875,000 and a net result of DKK -61,325,000 compared with DKK -13,215,000 the year before. Equity in the 2025 report amounted to DKK 32,493,000.
Source: annual report 2025, Danish Business Authority
The financial health of Drug Development Consulting BidCo ApS shows significant concerns, particularly with its profitability. Over the past four years, the company has consistently reported losses, culminating in a profit of -61,325,000 DKK in 2025, despite a gross profit of 5,875,000 DKK. Equity has decreased from 78,983,000 DKK in 2024 to 32,493,000 DKK in 2025, indicating a troubling decline. The lack of disclosed revenue raises questions about its operational viability, while the gross profit margins suggest potential for improvement if costs can be controlled. Positioned within the management consulting industry, the company faces challenges in achieving sustainable growth amidst its current financial trajectory.
AI-generated summary · Generated 14/08/2026
Selskabets formål er at eje kapitalandele i andre selskaber og anden i forbindelse hermed stående virksomhed, inklusiv, men ikke begrænset til, at yde management services til selskaber ejet fuldt eller delvist af selskabet.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 5.9 mio. | -61.3 mio. | 92 mio. | 32.5 mio. | 2 | |
| 202401/01/2024 – 31/12/2024 | 3.4 mio. | -13.2 mio. | 126 mio. | 79 mio. | 1 | |
| 202301/01/2023 – 31/12/2023 | 2.3 mio. | -9.4 mio. | 120.7 mio. | 70.2 mio. | 1 | |
| 202201/01/2022 – 31/12/2022 | 3.8 mio. | -11.8 mio. | 124.3 mio. | 71.8 mio. | 1 |
Compared to 11.555 companies in Virksomhedsrådgivning og anden ledelsesrådgivning
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Drug Development Consulting BidCo ApS is 42287067.
Drug Development Consulting BidCo ApS is owned by Drug Development Consulting Holding ApS.
The management of Drug Development Consulting BidCo ApS consists of René Holmen Pedersen.
The board of Drug Development Consulting BidCo ApS consists of Niels Peder Nielsen, Alejandra Maria Cristina Bonifacini Mørk and Rafael Natanek, with Niels Peder Nielsen as chair.
In 2025, Drug Development Consulting BidCo ApS reported a gross profit of DKK 5,875,000.
Drug Development Consulting BidCo ApS had an average of 2 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Address changed to Abildager 24, 2605 Brøndby (August 6, 2026).
Drug Development Consulting BidCo ApS has published its annual report for 2025. Gross profit came to DKK 5,875,000, and the net result was DKK -61,325,000.
Drug Development Consulting BidCo ApS has published its annual report for 2024. Gross profit came to DKK 3,438,000, and the net result was DKK -13,215,000.
As of February 28, 2025, Rasmus Koch Nelund has stepped down as director of Drug Development Consulting BidCo ApS.
Drug Development Consulting BidCo ApS has published its annual report for 2023. Gross profit came to DKK 2,320,000, and the net result was DKK -9,381,000.
As of April 25, 2024, Mette Kirstine Agger has left the board of directors of Drug Development Consulting BidCo ApS.
Drug Development Consulting BidCo ApS has published its annual report for 2022. Gross profit came to DKK 3,760,000, and the net result was DKK -11,831,000.
As of June 1, 2023, René Holmen Pedersen is registered as director of Drug Development Consulting BidCo ApS.
As of May 1, 2023, Rasmus Koch Nelund is registered as director of Drug Development Consulting BidCo ApS.
As of April 30, 2023, Alejandra Maria Cristina Bonifacini Mørk has stepped down as director of Drug Development Consulting BidCo ApS.
As of March 16, 2023, Niels Peder Nielsen has joined the board of directors of Drug Development Consulting BidCo ApS.
As of March 16, 2023, Alejandra Maria Cristina Bonifacini Mørk has joined the board of directors of Drug Development Consulting BidCo ApS.
As of March 16, 2023, Rafael Natanek has joined the board of directors of Drug Development Consulting BidCo ApS.
As of March 15, 2023, Rafael Natanek has left the board of directors of Drug Development Consulting BidCo ApS.
Drug Development Consulting BidCo ApS has published its interim report for the period April 8, 2021 – December 31, 2021.
As of May 17, 2021, Mette Kirstine Agger has joined the board of directors of Drug Development Consulting BidCo ApS.
As of May 17, 2021, Rafael Natanek has joined the board of directors of Drug Development Consulting BidCo ApS.
As of May 17, 2021, Redmar Koene has joined the board of directors of Drug Development Consulting BidCo ApS.
As of May 17, 2021, Alejandra Maria Cristina Bonifacini Mørk is registered as director of Drug Development Consulting BidCo ApS.
As of May 17, 2021, Jasper Michiel van Gorp has stepped down as director of Drug Development Consulting BidCo ApS.
As of April 8, 2021, EY Godkendt Revisionspartnerselskab has been appointed auditor of Drug Development Consulting BidCo ApS.
As of April 8, 2021, Jasper Michiel van Gorp is registered as director of Drug Development Consulting BidCo ApS.
As of April 8, 2021, Drug Development Consulting Holding ApS is registered as an owner of Drug Development Consulting BidCo ApS with an ownership share of 100%.
Drug Development Consulting BidCo ApS was founded on April 8, 2021.
Companies in the same industry and area
CVR 45675785
CVR 10101158
CVR 15367695
CVR 44526727
CVR 38532669
